Search hospitals > Virginia > Norfolk
Virginia Clinical Research, Inc.
Claim this profileNorfolk, Virginia 23507
Global Leader in Psoriasis
Global Leader in Atopic Dermatitis
Conducts research for Medical Device Dermatitis
Conducts research for Plaque Psoriasis
Conducts research for Acne
151 reported clinical trials
1 medical researcher
Summary
Virginia Clinical Research, Inc. is a medical facility located in Norfolk, Virginia. This center is recognized for care of Psoriasis, Atopic Dermatitis, Medical Device Dermatitis, Plaque Psoriasis, Acne and other specialties. Virginia Clinical Research, Inc. is involved with conducting 151 clinical trials across 95 conditions. There are 1 research doctors associated with this hospital, such as David M. Pariser.Top PIs
Clinical Trials running at Virginia Clinical Research, Inc.
Hidradenitis Suppurativa
HS
Skin Diseases
Hypotrichosis
Periprosthetic Bone Loss
Hairy Birthmarks
Hypersecretion
Congenital Hair Disorder
Skin Conditions
Alopecia Areata
Lutikizumab
for Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS . Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms. In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous injections of lutikizumab every week for 16 weeks, then either every week or every other week for 20 weeks. Period 3 is the Long Term Extentsion (LTE) and through Week 68, participants will continue to receive lutikizumab SC using the same assigned dosing regimen from the end of Period 2 for 16 weeks followed by open-label lutikizumab EOW for 140 weeks. Participants in the US that complete Periods 1 \& 2 will have the option to enroll in a 156-week open-label Sub-Study that will assess the long term safety and efficacy of lutikizumab in a prefilled pen. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.
Recruiting1 award Phase 31 criteria
EVO101 Cream
for Hidradenitis Suppurativa
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit. What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires. Participants will: Apply EVO101 topical cream 0.1% topically Visit the clinic four times unless the first and second appointment have to be done separately then there will be five clinic visits and one phone call over a twelve week period. Keep a dosing diary
Recruiting1 award Phase < 12 criteria
Upadacitinib
for Hidradenitis Suppurativa
This trial is testing if a daily pill called upadacitinib can help people with a painful skin condition called hidradenitis suppurativa (HS) who haven't responded to usual treatments. The study will involve adults and teenagers and will check for safety and effectiveness over time. Participants will be randomly given either the medication or a non-active pill, and their progress will be monitored through periodic medical check-ups.
Recruiting1 award Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Virginia Clinical Research, Inc.?
Virginia Clinical Research, Inc. is a medical facility located in Norfolk, Virginia. This center is recognized for care of Psoriasis, Atopic Dermatitis, Medical Device Dermatitis, Plaque Psoriasis, Acne and other specialties. Virginia Clinical Research, Inc. is involved with conducting 151 clinical trials across 95 conditions. There are 1 research doctors associated with this hospital, such as David M. Pariser.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.